Temozolomide (TMZ) is the current standard chemotherapy for glioblastoma (GBM), yet its therapeutic efficacy is severely hampered by poor chemical stability, and frequent development of resistance, particularly through MGMT upregulation [16]. Here, MGMT is linked to glioblastoma.